



Obecnie dostępne publikacje naukowe naszych pracowników:

[Justyna Dominika Kowalska, Pernille Ravn, Hanna Czeszko-Paprocka, Ewa Firląg-Burkacka, Andrzej Horban - "Single IFN-γ assay testing is of limited use for health care workers occupational exposure screening in a high tuberculosis prevalence country."](#)

[R. B. Podlasin, A. Wiercińska-Drapalo, A Olczak, M. Beniowski, T. Smiatcz, E. Malolepsza, J. Juszczyk, M. Leszczyn-Pynka, T. Mach, M. Mian, B. Knysz, A. Horban - "Opportunistic Infections and Other AIDS-defining Illnesses in Poland in 2000-2002"](#)

[W. Halota, D. Delić, Z. Nesić, D. Prokopowicz, R. Flisiak, J. Kuydowicz, M. Jabłkowski, J. Cianciara, T. Mach, R. Modrzewska, M. Fabri, D. Tomić, A. Horban, W. Kryczka, J. Schneider, G. Pearce - "A novel PrimeBoost Immunotherapy induces high levels of HBeAg loss after 14 weeks in Patients with HBeAg + Chronic Hepatitis B: A Phase IIa Clinical Trial"](#)

[J. D. Kowalska, E. Firląg-Burkacka, M. Niezabitowska, E. Bąkowska, J. Gizińska, J. Higersbereger, A. Ignatowska, G. Karczewski, P. Pulik, P. Świącki, A. Horban - "Tolerability and adherence to post-exposure prophylaxis of HIV infection in different exposure groups"](#)

[M. Niezabitowska, E. Firląg-Burkacka, J. D. Kowalska, E. Bąkowska, J. Gizińska, J. Higersberger, A. Ignatowska, G. Karczewski, P. Pulik, P. Świącki, A. Horban - "Analysis of consultations and tests schedule for HIV infection after exposure to potentially infectious material \(PIM\) in different exposure groups"](#)

[H. Berak, A. Kołakowska-Rządźka, M. Wasilewski, J. Stańczak, A. Horban - "Randomized, open label trial to come efficacy and safety of pegylated Interferon Alfa 2A v. Interferon Alfa 2b treatment of patient with chronic Hepatitis C - 12 weeks virological response among patients with genotype non 2/3 analysis "](#)

[J. Stańczak, U. Komorowska, E. Tobolewska, M. Majchrzak - "Współczesna diagnostyka zakażeń wirusem zapalenia wątroby typu C \(HCV\); Modern diagnostics of Hepatitis C Virus"](#)

[I. Szkop, H. Czeszko - Paprocka - "Walidacja metody pomiarowej"](#)

[S. Walmsley, A. Horban, R. Jain, C. Garris, T. Stark - "Fosamprenavir/ritonavir and Nelfinavir have Comparable Effects on Body Fat Changes in Antiretroviral-naive Patients: 48-Week Results from the SOLO Study"](#)

[AN. Phillips, B. Ledergerber, A. Horban, P. Reiss, A. Chiesi, O. Kirk, F. Mulcahy, M. Fisher, L. Machala, JD. Lundgren \(for the EuroSIDA Study group\) - " Rate of viral rebound in 539 patients with < 50 copies/mL on efavirenz-containing regimens, according to concomitant use of 3TC or ddI"](#)

[A. Mocroft, B. Ledergerber, JP. Viard, S. Staszewski, M. Murphy, A. Chiesi, A. Horban, AB. Hansen, AN. Phillips, JD. Lundgren \(for the EuroSIDA study group\) - " Time to Triple Drug Class Failure after Initiation of HAART"](#)

[A. Mocroft, B. Ledergerber, JP. Viard, S. Staszewski, M. Murphy, A. Chiesi, A. Horban, A-B. E. Hansen, AN. Phillips, JD. Lundgren \(for the EuroSIDA study group\) - "Time to triple drug class antiretroviral treatment failure after initiation of HAART: Results from the EuroSIDA study group"](#)

[S. Walmsley, A. Horban, R. Jain , C. Garris, T. Stark - " Fosamprenavir/ritonavir and Nelfinavir have Comparable Effects on Body Fat Changes in Antiretroviral-naive Patients: 48-Week Results from the SOLO Study"](#)

[H. Czeszko-Paprocka, C. Szczerbińska, M. Suwała, Z. Żuk, K. Roze - "Ocena analizatora chemii klinicznej Pentra 400 firmy Horiba ABX"](#)

[W. Banister, L. Ruiz, C. Loveday, S. Vella, K. Zilmer, D.Podlekareva, B. Knysz, A. Philips, J. Lundgren, A. Mocroft - "HIV1 Subtypes and Virological Response to HAART in Europe"](#)

[D.A.M.C. van de Vijver, A.M.J. Wensing, G. Angarano, B. Asjö, C. Balotta, E. Boeri, R. Camacho, M-L. Chaix, D. Costagliola, E.L.M. Op de Coul, A. de Luca, I. Maljkovic, C. de Mendoza, I. Derdelinckx, Z. Grossman, O. Hamouda, A. Hatzakis, I.M. Hoepelman, R. Hemmer, A. Horban, K. Korn, C. Kücherer, T. Leitner, C. Loveday, E. MacRae, L. Meyer, C.](#)

[Nielsen, V. Ormaasen, L. Perrin, D. Paraskevis, E. Puchhammer-Stöckl, L. Ruiz, .M Salminen, J.C.C. Schmit, F. Schneider, R. Schuurman, V. Soriano, G. Stanczak, M. Stanojevic, A-M. Vandamme, K. Van Laethem, M. Violin, K. Wilbe, S. Yerly, M. Zazzi, C.A.B. Boucher \(on behalf of the SPREAD Programme\) - "Potential impact of differences in frequency of minor substitutions between HIV-1 subtypes on the genetic barrier for resistance to protease inhibitors"](#)

[RB Pollard, M Thompson, C Hicks, B Grinsztejn, A Horban, P Cernohous, J Omachi, M Norton, M King, S Brun - "Phase 3 comparison of lopinavir/ritonavir vs. investigator-selected protease inhibitors in single PI-experienced, NNRTI-naive patients: 48-week results of study M98-888"](#)

[H. Berak - "Efekty leczenia lamiwudyną przewlekłych wirusowych zapaleń wątroby typu B na podstawie materiału własnego"](#)